Aurora Cannabis (TSX:ACB) issued an update on its international operations to shareholders.
As quoted in the press release:
The Company has successfully shipped cultivars from its Mountain facility to Denmark to commence populating the Phase I Aurora Nordic facility, a 100,000 square foot, retrofitted hybrid greenhouse, which will be ramping up to full production capacity of 8,000 [kilograms] per year of medical cannabis over the coming months. Aurora Nordic is a 51 [percent]Aurora owned subsidiary owned in partnership with Alfred Pederson & Son. Both the Phase I facility and Phase II, a 1,000,000 square foot, hybrid greenhouse facility with a cultivation capacity of more than 120,000 [kilograms] per year, have been designed by Aurora Larssen Projects Ltd. (“ALPS”), and will be completed to EU GMP standards, incorporating leading edge technologies.
Following a provisional EU GMP certification of a single shipment, as announced on July 11, 2018, Aurora’s new wholly-owned subsidiary, MedReleaf Corp., has now received full EU GMP (Good Manufacturing Practices) certification for its Markham facility.
In total globally, there are currently only 6 EU GMP certified cannabis production facilities, two of which are based in Canada and belong to Aurora. Through Pedanios, Aurora also owns an EU GMP certified distribution center for medical cannabis based in Germany. The new certification will increase product availability for the rapidly growing, higher-margin and heavily regulated EU market. All of the Company’s facilities are being designed and built to EU GMP standards.